Cardiovascular Disease in Inflammatory
Arthritis: Getting to the Heart of the Matter
Release Date: December 15, 2009
Expiration Date: December 15, 2011
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Estimated Time of Completion: 45 minutes
Description
Patients with inflammatory arthritis are at increased risk for cardiovascular disease. Studies have shown a clear link between inflammatory
mediators and the development of cardiovascular disease, which has led to research on inhibiting the production of inflammatory cytokines. In clinical trials using TNF inhibitors, most data suggest that blocking TNF production can decrease the incidence of some cardiovascular
events. However, TNF inhibitors have been associated with increases in other cardiovascular diseases, resulting in their contraindication in
these patient populations. Clinical trials with investigational interleukin-receptor antagonists have shown positive results on some systemic
inflammatory markers.
These research efforts have created a need for medical education providing evidence-based discussions of advances in cytokine inhibition and their effect on the care of patients with cardiovascular disease associated with inflammatory arthritis. This includes a review of the biologic mechanisms, potential therapeutic options for this patient population, risk-benefit ratios of each, and specific patient-selection criteria.
Objectives
On completion of this activity, participants should be able to:
- Review the epidemiology of increased cardiovascular morbidity and mortality associated with inflammatory arthritis.
- Discuss how immune-mediated pathways in atherosclerosis may be associated with inflammatory arthritis.
- Analyze emerging research on biomarkers being studied for cardiovascular disease in inflammatory arthritis.
- Explain how cytokines and other therapies for inflammatory arthritis may affect the outcome of patients with inflammatory arthritis.
- Recognize the need for early detection, risk stratification, and treatment guidelines for cardiovascular disease in inflammatory arthritis.
- Describe state-of-the-art noninvasive imaging for early cardiovascular disease in inflammatory arthritis.
Target Audience
This activity is designed to increase the knowledge of rheumatologists, cardiologists, and other interested healthcare professionals regarding
the biology and treatment of cardiovascular diseases associated with inflammatory arthritis, with the ultimate goal of improving the care of
patients with these conditions.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Directors
| Leonard H. Calabrese, DO Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Vice Chairman Department of Rheumatic & Immunologic Diseases R.J. Fasenmyer Chair of Clinical Immunology Cleveland Clinic Cleveland, Ohio |
Elaine Husni, MD, MPH Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Director, Clinical Outcomes Research Director, Arthritis and Musculoskeletal Treatment Center Department of Rheumatic & Immunologic Diseases Orthopaedic & Rheumatologic Institute Cleveland Clinic Cleveland, Ohio |
Faculty
| Joan M. Bathon, MD Professor of Medicine Deputy Director, Division of Rheumatology Director, The Johns Hopkins Arthritis Center Johns Hopkins University Baltimore, Maryland |
Stanley Hazen, MD, PhD Head of the Section for Preventive Cardiology and Rehabilitation Director for the Center for Cardiovascular Diagnostics and Prevention Departments of Cell Biology and Cardiovascular Medicine Cleveland Clinic Cleveland, Ohio |
| Steven Nissen, MD Chairman, Department of Cardiovascular Medicine Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western University Director, Joseph J. Jacobs Center for Heart and Vascular Institute Cleveland Clinic Cleveland, Ohio |
Josef Smolen, MD Professor of Medicine and Chairman Division of Rheumatology Internal Medicine III Medical University of Vienna Vienna, Austria |
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship, which in the context of their presentation(s), could be perceived as a potential conflict of interest:
| Joan M. Bathon, MD | ||
| Consulting: | Crescendo Biosciences; Roche | |
| Independent Contractor: | Amgen; Bristol-Myers Squibb; Biogen-IDEC | |
| Leonard Calabrese, DO | ||
| Consulting: | Elan; Roche | |
| Consulting, Teaching and Speaking: | Abbott; Amgen; Centocor; Genentech; Wyeth | |
| Stanley Hazen, MD, PhD | ||
| Consulting: | BG Medicine; Biophysicial Corp. | |
| Consulting & Board Membership: | PrognostiX | |
| Consulting, Teaching and Speaking: | AstraZeneca; Merck & Co.; Pfizer; Wyeth | |
| Josef Smolen, MD | ||
| Advisory Committee and Review Panel: | Abbott; Amgen; AstraZeneca; Centocor; Novartis; Pfizer; Roche; Schering-Plough; UCB; Wyeth | |
| Consulting: | Abbott; Amgen; UCB | |
| Research, Teaching and Speaking: | Abbott; Centocor; Roche; Schering-Plough; UCB; Wyeth | |
The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:
Elaine Husni, MD, MPH
Steven Nissen, MD
The Cleveland Clinic Foundation Center for Continuing Education acknowledges
an educational grant for support of this activity from:
Roche
This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education
and the RJ Fasenmyer Center for Clinical Immunology.
